Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects

Neuroendocrinology

Volumn 67, Issue 2, 1998, Pages 126-138

  Sundström, Inger ^a   Andersson, Agneta ^b   Nyberg, Sigrid ^a   Ashbrook, Donald ^c   Purdy, Robert H ^d   Bäckström, Torbjörn ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c Department of Pharmacokinetics and Drug Metabolism   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

aminobutyric acid; Clinical neuroendocrinology; Gonadal steroids; Premenstrual syndrome

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ELTANOLONE; NEUROSTEROID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; FOLLICULAR PHASE; HUMAN; LUTEAL PHASE; MENSTRUAL CYCLE; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; SACCADIC EYE MOVEMENT; SEDATION;

ADULT; AFFECT; BEHAVIOR; FEMALE; FOLLICULAR PHASE; HUMANS; HYPNOTICS AND SEDATIVES; LUTEAL PHASE; MENSTRUAL CYCLE; PREGNANOLONE; PREMENSTRUAL SYNDROME; SACCADES;

EID: 0031962178     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054307     Document Type: Article

References (50)

1. Bäckström T, Sanders D, Leask R, Davidson D, Warner P, Bancroft J: Mood, sexuality, hormones, and the menstrual cycle. II. Hormone levels and their relationship to the premenstrual syndrome. Psychosom Med 1983;45:503-507.
2. Halbreich U: Gonadal hormones and antihormones, serotonin and mood. Psychopharmacol Bull 1990;26:291-295.
3. Halbreich U, Piletz JE, Carson S, Halaris A, Rojansky N: Increased imidazoline and alpha-2-adrenergic binding in platelets of women with dysphoric premenstrual syndromes. Biol Psychiatry 1993;34:676-686.
4. Sundström I, Ashbrook D, Bäckström T: Reduced benzodiazepine sensitivity in patients with premenstrual syndrome, a pilot study. Psychoneuroendocrinology 1997;22:25-38.
5. Hammarbäck S, Bäckström T: Induced anovulation as treatment of premenstrual tension syndrome. Acta Obstet Gynecol Scand 1988;67:159-166.
6. Hammarbäck S, Ekholm UB, Bäckström T: Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. Acta Endocrinol (Copenh)1991;125:132-137.
7. Reame NE, Marshall JC, Kelch RP: Pulsatile LH secretion in women with premenstrual syndrome: Evidence for normal neuroregulation of the menstrual cycle. Psychoneuroendocrinology 1992;17:205-213.
8. Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM: Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986;232:1004-1007.
9. Carl P, Lang-Jensen T, Bach V, Jacobsen J, Sörensen B, Grälls M, Widlund L: Pharmacokinetics and pharmacodynamics of eltanolone (pregnanolone), a new steroid intravenous anaesthetic, in humans. Acta Anaesthesiol Scand 1994;38:734-741.
10. Carl P, Högskilde S, Nielsen JW, Sörensen MB, Lindholm M, Karlen B, Bäckström T: Pregnanolone emulsion. A preliminary pharmacokinetic and pharmacodynamic study of a new intravenous anaesthetic agent. Anaesthesia 1990;45:189-197.
11. Norberg L, Wahlström G, Bäckström T: The, anaesthetic potency of 3α-hydroxy-5α-pregnan-20-one and 3α-hydroxy-5β-pregnan-20-one determined with an intravenous EEG-threshold method in male rats. Pharmacol Toxicol 1987;61:42-47.
12. Landgren S, Aasly J, Bäckström T, Dubrovsky B, Danielsson E: The effect of progesterone and its metabolites on the interictal epileptiform discharge in the cat's cerebral cortex. Acta Physiol Scand 1987;131:33-42.
13. Wieland S, Lan NC, Mirasedeghi S, Gee KW: Anxiolytic activity of the progesterone metabolite 5α-pregnan-3α-ol-20-one. Brain Res 1991;565:263-268.
14. Wang MD, Seippel L, Purdy RH, Bäckström T: Relationship between symptom seventy and steroid variation in women with premenstrual syndrome: Study on serum pregnenolone, pregnenolone sulfate, 5α-pregnan-3,20-dione and 3α-hydroxy-5α-pregnan-20-one. J Clin Endocrinol Metab 1996;81:1076-1082.
15. Schmidt PJ, Purdy RH, Moore PH, Paul SM, Rubinow DR: Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J Clin Endocrinol Metab 1994;79:1256-1260.
16. Gentles W, Thomas EL: Effect of benzodiazepines upon saccadic eye movements in man. Clin Pharmacol Ther 1971;12:563-576.
17. Hommer DW, Matsuo V, Wolkowitz O, Chrousos G, Greenblatt DJ, Weingarter H, Paul SM: Benzodiazepine sensitivity in normal human subjects. Arch Gen Psychiatry 1986;43:542-551.
18. Roy-Burne PP, Cowley DS, Greenblatt DJ, Shader RI, Hommer D: Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry 1990;47:534-538.
19. Ball DM, Glue P, Wilson S, Nutt DJ: Pharmacology of saccadic eye movements in man. 1. Effects of the benzodiazepine receptor ligands midazolam and flumazenil. Psychopharmacology 1991;105:361-367.
20. Becker W: Metrics; in Wurtz RH, Goldberg ME (eds): The Neurobiology of Saccadic Eye Movements. Amsterdam, Elsevier Science, 1989, pp 13-67.
21. Young SW, Kuhar MJ: Autoradiographic localisation of benzodiazepine receptors in the brains of humans and animals. Nature 1979;280:393-395.
22. Hikosaka O, Wurtz RH: Modification of saccadic eye movements by GABA-related substances. I. Effect of muscimol and bicuculline in the monkey superior colliculus. J Neurophysiol 1985;53:266-291.
23. Hikosaka O, Wurtz RH: Modification of saccadic eye movements by GABA-related substances. II. Effect of muscimol and bicuculline in the monkey substantia nigra pars reticulata. J Neurophysiol 1985;53:292-308.
24. Becker W, Fuchs AF: Further properties of the human saccadic system: Eye movements and correction saccades with and without visual fixation points. Vision Res 1969;9:1247-1258.
25. Mercer AJ, Marshall RW, Richens A: Saccadic eye movements as a method of psychometric assessment; in Klepper ID, Saunders LD, Rosen M (eds): Ambulatory Anaesthesia and Sedation. Oxford, Blackwell, 1990, pp 88-105.
26. Hammarbäck S, Bäckström T, MacGibbon-Taylor B: Diagnosis of premenstrual tension syndrome: Description and evaluation of a procedure for diagnosis and differential diagnosis. J Psychosom Obstet Gynaecol 1989;10:25-42.
27. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, US Department of Health and Human Services, 1994, pp 714-718.
28. Wang MD, Wahlström G, Gee KW, Bäckström T: Potency of lipid emulsion and protein formulation of 5α-pregnanolone at induction of anaesthesia and the corresponding regional brain distribution. Br J Anaesth 1995;74:553-557.
29. Marshall RW, Griffiths AN, Richens A: A microcomputer system to assess CNS depression from the analysis of the dynamics of saccadic eye movements. Br J Clin Pharmacol 1985;20:304-305.
30. Marshall RW, Richens A: An IBM-based system for the generation, collection and analysis of saccadic and smooth pursuit eye movements. Br J Clin Pharmacol 1989;28:752-753.
31. Baloh RW, Sills AW, Kumley WE, Honrubia V: Quantitative measurement of saccade amplitude, duration, and velocity. Neurology 1975;25:1065-1070.
32. Bäckström T, Andersson A, Baird DT, Selstam G: The human corpus luteum secretes 5α-pregnan-3,20-dione. Acta Endocrinol (Copenh) 1986;111:116-121.
33. Coprechot C, Young J, Calvel M, Wehrey C, Veltz JN, Touyer G, Mouren M, Prasad WK, Banner C, Sjövall J, Baulieu EE, Robel P: Neurosteroids: 3α-Hydroxy-5α-pregnan-20-one and its precursors in the brain, plasma, and steroidogenic glands of male and female rats. Endocrinology 1993;133:1003-1008.
34. McCormack HM, Horne DJdL, Sheather S: Clinical application of visual analogue scales: A critical review. Psychol Med 1988;18:1007-1019.
35. Cowley DS, Roy-Burne PP, Radant A, Ritchie JC, Greenblatt DJ, Nemeroff CB, Hommer DW: Benzodiazepine sensitivity in panic disorder: Effects of chronic alprazolam treatment. Neuropsychopharmacology 1995;12:147-157.
36. Halbreich U, Petty F, Yonkers K, Kramer GL, Rush AJ, Bibi KW: Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder. Am J Psychiatry 1996;153:718-720,
37. Sundström I, Nyberg S, Bäckström T: Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology 1997;17:370-381.
38. Freeman EW, Rickels K, Sondheimer SJ, Polansky M: A double-blind trial of oral progesterone, alprazolam and placebo in treatment of severe premenstrual syndrome. JAMA 1995;274:51-57.
39. Harrison WM, Endicott J, Rabkin JG, Nee JC, Sandberg D: Treatment of premenstrual dysphoria with alprazolam and placebo. Psychopharmacol Bull 1987;23:150-153.
40. Harrison WM, Sandberg D, Gorman JM, Fyer M, Nee J, Uy J, Endicott J: Provocation of panic with carbon dioxide inhalation in patients with premenstrual dysphoria. Psychiatry Res 1989;27:183-192.
41. Sandberg D, Endicott J, Harrison W, Nee J, Gorman J: Sodium lactate infusion in late luteal phase dysphoric disorder. Psychiatry Res 1996;46:79-88.
42. Steiner M, Steinberg S, Stewart S, Carter D, Berger C, Reid R, Grover D, Streiner D, Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med 1995;332:1529-1534.
43. Johnson MR, Lydiard RB, Ballenger JC: Panic disorder. Pathophysiology and drug treatment. Drugs 1995;49:328-344.
44. A-receptor function: Molecular and physiological determinants; in Biggio G, Costa E (eds): GABAergic synaptic transmission. New York, Raven Press, 1992, pp 269-279.
45. Jäntti V, Lang AH, Keskinen E, Lehtinen I, Pakkanen A: Acute effects of intravenously given alcohol on saccadic eye movements and subjective evaluations of intoxication. Psychopharmacology 1983;79:251-255.
46. Sundström I, Bäckström T: Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome, an open trial. Psychoneuroendocrinology 1998; in press.
47. McLeod DR, Foster GV, Hoehn-Saric R, Svikis DS, Hipsley PA: Family history of alcoholism in women with generalized anxiety disorder who have premenstrual syndrome: Patient reports of premenstrual alcohol consumption and symptoms of anxiety. Alcohol Clin Exp Res 1994;18:664-670.
48. Choung CJ, Burgos DM: Medical history in women with premenstrual syndrome. J Psychosom Obstet Gynaecol 1995;16:21-27.
49. McAuley JW, Reynolds IJ, Kroboth FJ, Smith RB, Kroboth PD: Orally administered progesterone enhances sensitivity to triazolam in postmenopausal women. J Clin Psychopharmacol 1995;15:3-11.
50. Hammarbäck S, Damber J-E, Bäckström T: Relationship between symptom severity and hormone changes in women with premenstrual syndrome. J Clin Endocrinol Metab 1989;68:125-130.